Nix ๐ retweeted
Please share $NWBO Amazing cancer treatment made in USA but only available in the UK!
๐จ TODAY, I submitted my public comment to the FDA regarding its proposed Rare Disease Framework.
As the mother of a 19-year-old fighting an aggressive, deadly brain cancer, I have one urgent message:
Patients donโt just need faster drug approvals. They need ACCESS to promising treatments while theyโre still alive to benefit from them.
My comment shares Braelynโs extraordinary journey, the clinical evidence and long-term survivors associated with DCVax-L, and the enormous barriers American families face trying to access investigational treatments.
I also outline Braelynโs Bill, built around four fundamental patient rights:
โค๏ธ The Right to Know
โค๏ธ The Right to Preserve
โค๏ธ The Right to Choose
โค๏ธ The Right to Access
My most urgent request is Braelynโs Rule: Patients facing life-threatening diseases should be able to access investigational treatments through their physicians, with informed consent and manufacturer participation, without unnecessary regulatory obstacles.
We should not have to fly across an ocean to access a promising cancer treatment developed right here in America.
The FDAโs new framework must measure success not just by how quickly treatments are evaluated, but by whether patients can actually access them while thereโs still time.
Iโm sharing my full four-page public comment because this fight is about far more than my daughter.
Itโs about every family who deserves the opportunity to fight for their loved oneโs life.
Please read and share. โค๏ธ๐
#BraelynsBill #DCVaxForBraelyn #RareDiseases
Nix ๐ retweeted
FDA has responded to my $NWBO #DCVax proposal.
Today, the Rare Disease Innovation Hub confirmed that my submission "has been received and will be routed to the appropriate centers for consideration."
I submitted a 21-page proposal advocating for DCVax-L and DCVax-Direct under the Rare Disease Framework, beginning with rare cancers.
The future I am advocating is a system built to handle personalization from the start.
DCVax-L uses a patient's tumor material to load their dendritic cells. DCVax-Direct places prepared dendritic cells into a tumor to acquire tumor material there. Each program has its own evidence requirements. Both make the same larger question impossible to ignore: how do we evaluate a treatment whose patient-specific inputs are supposed to vary?
The framework should distinguish intentional personalization from manufacturing inconsistency. Define what must remain reliable, what changes with each patient, and how those differences affect safety and benefit.
That distinction can shape the next generation of cancer treatment:
1. Preserve options before surgery. Plan consent, diagnostic allocation, tissue handling and storage while suitable material is still available.
2. Build on what has been learned. State which clinical and manufacturing evidence can be reused, where new evidence is essential, and how to test applications across rare cancer types.
3. Make every study answer a clear question. Connect mechanism, measured biological activity and meaningful patient outcomes. Use external controls and Bayesian methods when their assumptions can be justified and tested.
4. Plan for continuing care. Identify who is responsible for supply, qualified treatment sites, lawful access and financing. Beginning treatment and being able to continue it belong in the same plan.
These are my recommendations as an independent physician and patient advocate. I do not speak for Northwest Biotherapeutics.
FDA's reply gives us a clear next step: keep the evidence and patient experience in front of the people building this framework. Families can explain where the current system breaks down and what a workable path must provide.
The measure of progress will be a family that knows what comes next, who is responsible, and how to reach them while there is still time.
Read the proposal:
drive.google.com/file/d/1qvBโฆ
Add your own comment by December 11, 2026:
regulations.gov/commenton/FDโฆ
#RareDisease #RareCancer #Immunotherapy #PatientAdvocacy #GBM
$NWBO #DCVax #DCVaxForBraelyn #RareCancer #PatientAdvocacy #GBM
๐ฃ ๐๐ฒ๐น๐ฝ ๐ฝ๐๐ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐๐ ๐ถ๐ป๐๐ผ ๐๐ต๐ฒ ๐ฟ๐ฒ๐ฐ๐ผ๐ฟ๐ฑ.
FDA is taking public comment on its new Rare Disease Framework. A proposal for DCVax-L and DCVax-Direct is already in the docket, with the evidence, tissue and access questions laid out in one place.
Supporting it is one way to speak with a unified voice. A hundred different asks scatter FDAโs attention. A hundred people behind one documented request give the agency something it can act on.
1๏ธโฃ ๐ฅ๐ฒ๐ฎ๐ฑ ๐๐ต๐ฒ ๐ฝ๐ฟ๐ผ๐ฝ๐ผ๐๐ฎ๐น.
drive.google.com/file/d/1qvBโฆ
2๏ธโฃ ๐๐ผ๐บ๐บ๐ฒ๐ป๐ ๐๐ผ ๐๐๐.
regulations.gov/commenton/FDโฆ
Write it in your own words. Three things to cover:
โข Who you are: patient, caregiver, clinician, researcher or shareholder.
โข That you support the DCVax-L and DCVax-Direct proposal submitted October 29, 2026 (tracking number mvt-lzyl-zjmn), and want FDA to clarify evidence requirements, tissue preservation and a practical path to patient access.
โข What only you can say: what waiting has cost you or someone you love.
Same ask, your own words. FDA weighs arguments, not counts, and a hundred copies of one letter count as one.
๐
๐๐ฒ๐ฎ๐ฑ๐น๐ถ๐ป๐ฒ: December 11, 2026, 11:59 p.m. Eastern.
Comments are public. Use your name if you can, leave out private medical details, and save your confirmation number.
๐ข๐ป๐ฒ ๐ฎ๐๐ธ. ๐ ๐ฎ๐ป๐ ๐๐ผ๐ถ๐ฐ๐ฒ๐. ๐ฌ๐ผ๐๐ฟ ๐ฒ๐
๐ฝ๐ฒ๐ฟ๐ถ๐ฒ๐ป๐ฐ๐ฒ ๐ฏ๐ฒ๐น๐ผ๐ป๐ด๐ ๐ถ๐ป ๐๐ต๐ฒ ๐ฟ๐ฒ๐ฐ๐ผ๐ฟ๐ฑ.
Nix ๐ retweeted
NorthWest Biotherapeutics Inc ( $NWBO ): Attached photo is a copy of my email I s... investorshub.advfn.com/boardโฆ via @Investors_Hub
$nwbo. If you have been around for almost a decade, like I have, then you understand the parties involved and the implication of this response is as good as itโs gonna get prior to approval.
Nix ๐ retweeted
๐จ TODAY, I submitted my public comment to the FDA regarding its proposed Rare Disease Framework.
As the mother of a 19-year-old fighting an aggressive, deadly brain cancer, I have one urgent message:
Patients donโt just need faster drug approvals. They need ACCESS to promising treatments while theyโre still alive to benefit from them.
My comment shares Braelynโs extraordinary journey, the clinical evidence and long-term survivors associated with DCVax-L, and the enormous barriers American families face trying to access investigational treatments.
I also outline Braelynโs Bill, built around four fundamental patient rights:
โค๏ธ The Right to Know
โค๏ธ The Right to Preserve
โค๏ธ The Right to Choose
โค๏ธ The Right to Access
My most urgent request is Braelynโs Rule: Patients facing life-threatening diseases should be able to access investigational treatments through their physicians, with informed consent and manufacturer participation, without unnecessary regulatory obstacles.
We should not have to fly across an ocean to access a promising cancer treatment developed right here in America.
The FDAโs new framework must measure success not just by how quickly treatments are evaluated, but by whether patients can actually access them while thereโs still time.
Iโm sharing my full four-page public comment because this fight is about far more than my daughter.
Itโs about every family who deserves the opportunity to fight for their loved oneโs life.
Please read and share. โค๏ธ๐
#BraelynsBill #DCVaxForBraelyn #RareDiseases
Nix ๐ retweeted
Replying to @elonmusk
@elonmusk surrounds himself with brilliant engineers. $NWBO ยดs Linda Powers surrounds herself with brilliant scientists, clinicians, manufacturing experts and strategists. Different industries, same philosophy: build something extraordinary by bringing extraordinary people together.
Linda Liau, Laura Posner, Annalisa Jenkins, Joanna Stanson, Marnix Bosch, Pawel Kalinski just to name a few
Replying to @elonmusk
The company that gave this young girl a clear MRI and no evidence of disease has the ultimate Banger Treatment - check it out, hear her story. The cure to cancer has never been closer and it is not coming from Big Pharma
I have been waiting almost 3 years to write these words:
NO EVIDENCE OF DISEASE. ๐โค๏ธ
Today we met with Braelynโs neurosurgeon, Dr. Linda Liau at UCLA (telehealth).
When our local radiologist read Braelynโs August 28 MRI as โno evidence of disease recurrence,โ we were thrilledโbut I was afraid to fully exhale.
I knew Dr. Liau and the UCLA tumor board would scrutinize every millimeter of those images.
What if they saw something the local radiologist missed?
Today, Dr. Liau told us that she and the tumor board had thoroughly reviewed Braelynโs MRI.
They were amazed.
There is NO VISIBLE TUMOR.
Even the ~10% Dr. Liau had to leave behind during surgery because of its intimate involvement with critical structures is no longer visible.
She emphasized how amazed and pleased the entire tumor board was by such a complete response at this point.
Her assessment: the prior radiation and the ongoing DCVax appear to be working very well.
Their recommendation after also reviewing the Keytruda regimen Braelyn recently started?
KEEP DOING WHAT SHEโS DOING.
๐ญ๐
First and foremost, we give ALL thanks and glory to God.
People all over the world have prayed for this girl. I cannot begin to express how humbled and grateful we are.
But tonight I also cannot stop thinking about how close Braelyn came to never having this opportunity.
Earlier this year, her tumor was enormous and growing rapidly.
We sought help from multiple surgeonsโincluding at prestigious institutions.
We were told further surgery was too risky.
We were offered the same old options: chemotherapy and photon radiation that would affect most of her brain, given the size of her tumor.
Her tumor is MGMT-unmethylated, so for Braelyn, chemo was all risk with little to no benefit.
And then a stranger I met here on X changed everything. @ThomasOwenMcCa1 connected us with Dr. Liau.
After reviewing Braelynโs case, one of the first things she said was:
โThis girl needs surgery right away.โ
I told her we knew that. We just couldnโt find anyone willing to do it.
I asked if SHE would.
โIf you can get her to me, I will do her surgery.โ
We got Braelyn to UCLA.
Within two weeks, Dr. Liau operated and removed ~90% of a massive tumor spanning three lobes, stopping where continuing would risk critical structures.
And this time, her tumor tissue was PROPERLY PRESERVED.
That tissue was ultimately sent to England and used to manufacture Braelynโs personalized DCVax vaccine.
She has now received 3 induction doses + her first booster.
And today?
The tumor that Dr. Liau had to leave behind is no longer visible on MRI.
Think about that.
And then think about what could have happened if we had simply accepted โthereโs nothing else we can do.โ
THIS is why I will not stop advocating for reform.
Patients should not have to find potentially life-saving treatment options accidentally through strangers on social media.
Patients should be told about legitimate investigational options when standard treatment offers little hope.
Patients undergoing tumor surgery should be informed BEFORE surgery about preservation of tissue that could potentially be used for personalized treatments.
And patients should have the right to make informed decisions about which risks they are willing to take.
Promising science means very little if the patients who need it cannot access it.
Braelyn is living proof of why access matters.
Tonight, though, advocacy can wait for just a moment.
Tonight Iโm her mom.
And I finally get to say the words I have begged God to someday let me say:
NO EVIDENCE OF DISEASE.
Thank You, God.
Thank you, Dr. Liau.
Thank you to everyone who opened a door, donated, shared her story, fought for her and prayed for our girl.
There is always light, even in the darkest places.
Tonight that light is shining incredibly bright. โค๏ธ๐
#DCVaxForBraelyn #CureNotCovered
@greta
@kshaughnessy2
@andrewcaravello
Nix ๐ retweeted
It is with the deepest ache in our souls that we share the passing of our baby girl, Laurel, on 10โข27โข26.
Though her time on Earth was brief, she was endlessly loved. We are forever blessed to have held her, loved her, and been together as a family in her final moments.
Nix ๐ retweeted
Replying to @mfhugo1
Thank you for advocating for the rare disease community, especially while recovering from surgery. Wishing you a smooth recovery.
Say the words, Mike #DCVax $NWBO. With it comes a dedicated group of investors and patient advocates. We're behind you on this Mike.
Yesterday, I had the privilege of attending the FDAโs Rare Disease Framework Initiative public meeting.
I had brain surgery for recurrent Glioblastoma (GBM) just a few weeks ago, but I flew to Maryland for this meeting because this new framework has the potential to change the future of GBM.
Iโve fought this disease for 4.5 years, using every tool available. But my best chance now, at recurrence, is a treatment that is currently only accessible in the UK, a personalized cancer vaccine called DCVaxL.
I made sure to freeze my tumor tissue specifically so I could have a chance at getting this vaccine. I should find out within the next week or two whether my tissue sample is adequate for vaccine manufacturing. More details to come.
@HollensbeAmanda @LoriMills4CA42 @andrewcaravello @intrstedobservr
Yesterday, I had the privilege of attending the FDAโs Rare Disease Framework Initiative public meeting.
I had brain surgery for recurrent Glioblastoma (GBM) just a few weeks ago, but I flew to Maryland for this meeting because this new framework has the potential to change the future of GBM.
Iโve fought this disease for 4.5 years, using every tool available. But my best chance now, at recurrence, is a treatment that is currently only accessible in the UK, a personalized cancer vaccine called DCVaxL.
I made sure to freeze my tumor tissue specifically so I could have a chance at getting this vaccine. I should find out within the next week or two whether my tissue sample is adequate for vaccine manufacturing. More details to come.
@HollensbeAmanda @LoriMills4CA42 @andrewcaravello @intrstedobservr
Nix ๐ retweeted
Replying to @m_goes_distance
Forgot to mention $nwbo cancer vaccine DCVax-L for GBM cured a patient in the news last few weeks and has great results pending approval from @MHRAgovuk any day now. Best part is their Direct platform has 10x the potential of L.
Nix ๐ retweeted
$NWBO
The FDA can stop searching for another treatment for brain tumors. It should already have the data showing that DCVax-L is the best option available. Approve it, so more lives can be saved. Just a reminder. The MHRA has already fallen behind, after monitoring DCVax-L through the UK Specials program for more than 14 years.
If the FDA had held its Public Meeting on the Rare Disease Drug Development Framework before the MOU, it would have looked proactive. Coming after, it looks reactive.
youtu.be/6kFkeH6eW0c?t=8064
xitter.gq/d_stock07734/status/19โฆ
$NWBO #DCVax #DCVaxForBraelyn #RareDisease #RareCancer #Immunotherapy #PatientAdvocacy #CancerResearch
๐งฌ ๐ง๐ต๐ถ๐ ๐บ๐ผ๐ฟ๐ป๐ถ๐ป๐ด ๐ ๐๐ผ๐ผ๐ธ ๐๐ต๐ฒ ๐ฐ๐ฎ๐๐ฒ ๐ณ๐ผ๐ฟ ๐๐๐ฉ๐ฎ๐
๐๐ผ ๐๐ต๐ฒ ๐๐๐.
A 21-page proposal with 52 cited sources, filed to the public docket for FDAโs ๐ฅ๐ฎ๐ฟ๐ฒ ๐๐ถ๐๐ฒ๐ฎ๐๐ฒ ๐๐ฟ๐ฎ๐บ๐ฒ๐๐ผ๐ฟ๐ธ and sent to the Rare Disease Innovation Hub with a one-page summary. Both are in the images.
My advocacy is specific: ๐๐๐ฉ๐ฎ๐
-๐ ๐ฎ๐ป๐ฑ ๐๐๐ฉ๐ฎ๐
-๐๐ถ๐ฟ๐ฒ๐ฐ๐, beginning with rare cancers. I submitted this in my personal capacity as a physician and patient advocate. I am not affiliated with Northwest Biotherapeutics and do not speak for the company.
The ask: one published development example connecting three plans, the evidence, the tissue and manufacturing, and the patientโs route to care, so that a patient can begin treatment ๐ฎ๐ป๐ฑ ๐ฐ๐ผ๐ป๐๐ถ๐ป๐๐ฒ ๐ถ๐. I asked FDA to name a coordinating office, publish a workplan within 90 days of the comment period closing, and include patients before key decisions are fixed.
One distinction runs through the whole proposal: more analyses of the same patients are not independent evidence.
FDA is inviting patients and advocates to shape this framework now, while it is still being designed. Behind every question about evidence, tissue or access is a family trying to keep someone alive.
๐ฅ๐ฎ๐ฟ๐ฒ ๐๐ต๐ผ๐๐น๐ฑ ๐ฑ๐ฒ๐๐ฐ๐ฟ๐ถ๐ฏ๐ฒ ๐๐ต๐ฒ ๐ฑ๐ถ๐๐ฒ๐ฎ๐๐ฒ. ๐๐ ๐๐ต๐ผ๐๐น๐ฑ ๐ป๐ฒ๐๐ฒ๐ฟ ๐ฑ๐ฒ๐๐ฐ๐ฟ๐ถ๐ฏ๐ฒ ๐๐ต๐ฒ ๐ฎ๐๐๐ฒ๐ป๐๐ถ๐ผ๐ป ๐ถ๐๐ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐๐ ๐ฟ๐ฒ๐ฐ๐ฒ๐ถ๐๐ฒ.
๐ Docket: FDA-2026-N-12214
โ
Comment tracking: mvt-lzyl-zjmn
๐ drive.google.com/file/d/1qvBโฆ
Nix ๐ retweeted
Replying to @JoeyMannarino
Unfortunately she will never face consequences for all the damage she has done. Sheโll ride off into the sunset with her millions.
Nix ๐ retweeted
$NWBO #DCVax #DCVaxForBraelyn #RareDisease #RareCancer #Immunotherapy #PatientAdvocacy #CancerResearch
๐งฌ ๐ง๐ต๐ถ๐ ๐บ๐ผ๐ฟ๐ป๐ถ๐ป๐ด ๐ ๐๐ผ๐ผ๐ธ ๐๐ต๐ฒ ๐ฐ๐ฎ๐๐ฒ ๐ณ๐ผ๐ฟ ๐๐๐ฉ๐ฎ๐
๐๐ผ ๐๐ต๐ฒ ๐๐๐.
A 21-page proposal with 52 cited sources, filed to the public docket for FDAโs ๐ฅ๐ฎ๐ฟ๐ฒ ๐๐ถ๐๐ฒ๐ฎ๐๐ฒ ๐๐ฟ๐ฎ๐บ๐ฒ๐๐ผ๐ฟ๐ธ and sent to the Rare Disease Innovation Hub with a one-page summary. Both are in the images.
My advocacy is specific: ๐๐๐ฉ๐ฎ๐
-๐ ๐ฎ๐ป๐ฑ ๐๐๐ฉ๐ฎ๐
-๐๐ถ๐ฟ๐ฒ๐ฐ๐, beginning with rare cancers. I submitted this in my personal capacity as a physician and patient advocate. I am not affiliated with Northwest Biotherapeutics and do not speak for the company.
The ask: one published development example connecting three plans, the evidence, the tissue and manufacturing, and the patientโs route to care, so that a patient can begin treatment ๐ฎ๐ป๐ฑ ๐ฐ๐ผ๐ป๐๐ถ๐ป๐๐ฒ ๐ถ๐. I asked FDA to name a coordinating office, publish a workplan within 90 days of the comment period closing, and include patients before key decisions are fixed.
One distinction runs through the whole proposal: more analyses of the same patients are not independent evidence.
FDA is inviting patients and advocates to shape this framework now, while it is still being designed. Behind every question about evidence, tissue or access is a family trying to keep someone alive.
๐ฅ๐ฎ๐ฟ๐ฒ ๐๐ต๐ผ๐๐น๐ฑ ๐ฑ๐ฒ๐๐ฐ๐ฟ๐ถ๐ฏ๐ฒ ๐๐ต๐ฒ ๐ฑ๐ถ๐๐ฒ๐ฎ๐๐ฒ. ๐๐ ๐๐ต๐ผ๐๐น๐ฑ ๐ป๐ฒ๐๐ฒ๐ฟ ๐ฑ๐ฒ๐๐ฐ๐ฟ๐ถ๐ฏ๐ฒ ๐๐ต๐ฒ ๐ฎ๐๐๐ฒ๐ป๐๐ถ๐ผ๐ป ๐ถ๐๐ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐๐ ๐ฟ๐ฒ๐ฐ๐ฒ๐ถ๐๐ฒ.
๐ Docket: FDA-2026-N-12214
โ
Comment tracking: mvt-lzyl-zjmn
๐ drive.google.com/file/d/1qvBโฆ
Nix ๐ retweeted
$NWBO
โ ๐ง๐ต๐ถ๐ ๐บ๐ผ๐ฟ๐ป๐ถ๐ป๐ด ๐ ๐๐ผ๐ผ๐ธ ๐๐ต๐ฒ ๐ฐ๐ฎ๐๐ฒ ๐ณ๐ผ๐ฟ ๐๐๐ฉ๐ฎ๐
๐๐ผ ๐๐ต๐ฒ ๐๐๐.
A 21-page proposal with 52 cited sources, filed to the public docket for FDAโs ๐ฅ๐ฎ๐ฟ๐ฒ ๐๐ถ๐๐ฒ๐ฎ๐๐ฒ ๐๐ฟ๐ฎ๐บ๐ฒ๐๐ผ๐ฟ๐ธ and sent to the Rare Disease Innovation Hub with a one-page summary. Both are in the imagesโฆโ
- @andrewcaravello
Details in post below
๐๐๐
@SpimacoAddwaeih @aljedai @MHRAgovuk @NHS @NHSEngland @NHSBT @FDA @DrOzCMS @realDonaldTrump
$NWBO #DCVax #DCVaxForBraelyn #RareDisease #RareCancer #Immunotherapy #PatientAdvocacy #CancerResearch
๐งฌ ๐ง๐ต๐ถ๐ ๐บ๐ผ๐ฟ๐ป๐ถ๐ป๐ด ๐ ๐๐ผ๐ผ๐ธ ๐๐ต๐ฒ ๐ฐ๐ฎ๐๐ฒ ๐ณ๐ผ๐ฟ ๐๐๐ฉ๐ฎ๐
๐๐ผ ๐๐ต๐ฒ ๐๐๐.
A 21-page proposal with 52 cited sources, filed to the public docket for FDAโs ๐ฅ๐ฎ๐ฟ๐ฒ ๐๐ถ๐๐ฒ๐ฎ๐๐ฒ ๐๐ฟ๐ฎ๐บ๐ฒ๐๐ผ๐ฟ๐ธ and sent to the Rare Disease Innovation Hub with a one-page summary. Both are in the images.
My advocacy is specific: ๐๐๐ฉ๐ฎ๐
-๐ ๐ฎ๐ป๐ฑ ๐๐๐ฉ๐ฎ๐
-๐๐ถ๐ฟ๐ฒ๐ฐ๐, beginning with rare cancers. I submitted this in my personal capacity as a physician and patient advocate. I am not affiliated with Northwest Biotherapeutics and do not speak for the company.
The ask: one published development example connecting three plans, the evidence, the tissue and manufacturing, and the patientโs route to care, so that a patient can begin treatment ๐ฎ๐ป๐ฑ ๐ฐ๐ผ๐ป๐๐ถ๐ป๐๐ฒ ๐ถ๐. I asked FDA to name a coordinating office, publish a workplan within 90 days of the comment period closing, and include patients before key decisions are fixed.
One distinction runs through the whole proposal: more analyses of the same patients are not independent evidence.
FDA is inviting patients and advocates to shape this framework now, while it is still being designed. Behind every question about evidence, tissue or access is a family trying to keep someone alive.
๐ฅ๐ฎ๐ฟ๐ฒ ๐๐ต๐ผ๐๐น๐ฑ ๐ฑ๐ฒ๐๐ฐ๐ฟ๐ถ๐ฏ๐ฒ ๐๐ต๐ฒ ๐ฑ๐ถ๐๐ฒ๐ฎ๐๐ฒ. ๐๐ ๐๐ต๐ผ๐๐น๐ฑ ๐ป๐ฒ๐๐ฒ๐ฟ ๐ฑ๐ฒ๐๐ฐ๐ฟ๐ถ๐ฏ๐ฒ ๐๐ต๐ฒ ๐ฎ๐๐๐ฒ๐ป๐๐ถ๐ผ๐ป ๐ถ๐๐ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐๐ ๐ฟ๐ฒ๐ฐ๐ฒ๐ถ๐๐ฒ.
๐ Docket: FDA-2026-N-12214
โ
Comment tracking: mvt-lzyl-zjmn
๐ drive.google.com/file/d/1qvBโฆ
Nix ๐ retweeted
"WAIT... 'Kuru disease'? By now we should all know exactly how the 'Elites' get it....the same way it was transmitted among the Fore people of Papua New Guinea: through ritual cannibalism, specifically by consuming infected human brain tissue."
Nix ๐ retweeted
$nwbo
The momentum is palpable. I feel we are close to the end of a bumpy road and are about to hit the jet stream.
#DCVaxForBraelyn
#FDA
xitter.gq/i/trending/21154732712โฆ
Nix ๐ retweeted
$NWBO Right to try #Glioblastoma American product should be available in America!! ๐
$NWBO
โThe secret society that most brain cancer patients never hear aboutโฆโ
Nearly three years ago a prestigious cancer institute told Amanda Hollensbe her 16 year old daughter, Braelyn, had months to live.
They didnโt tell her about the long-term glioblastoma survivors.
But she found them.
And she says these survivors want โto shout their stories from the mountaintops.
They speak at conferences. They advocate for patients and theyโre even testifying in front of Congress.
Why is it that newly diagnosed patients and families arenโt told about them? โ
@HollensbeAmanda .
Long term glioblastoma survivor
@ThomasOwenMcCa1 heard Braelynโs story and reached out.
He connected Amanda to the long term survivor community and to his incredible surgeon, Dr Linda Liau.
And Thomas recently posted thisโฆ
โMy six month M.R.I was clear. Thanks to Dr. Cloughesy, Nanette Fong, & of course Dr. Linda Liau (my Neurosurgeon. NWBO DCVax. 11 years, 4 months, no tumor recurrence. Not badโ
xitter.gq/thomasowenmcca1/statusโฆ
And today, July 15, is National GBM Awareness Day
Tomorrow, July 16, Braelyn turns 19!
Share and repost in her honor
Amanda - Video #5,
Picture 1 - Braelyn
Picture 2 - Long Term Glioblastoma Survivors
@andrewcaravello @gr197667 @LisainNJUSA @RobertKennedyJr
Nix ๐ retweeted
Marty, per AI, $NWBO Autologous Therapies: For complex personalized cellular therapies (like DCVax-L), long delays historically stem from pre-approval inspection (PAI) findings or comparability studies regarding automated vs. manual mfgโฆtotal review timelines to 2 to 5 years.












































